Limitations.
The study was anticipated to enroll rapidly and was designed to minimize placebo enrollment in later cohorts by pooling data from placebo patients in earlier cohorts. However, slower enrollment than anticipated and rapid roll out of vaccines led to differences in key baseline characteristics such that the cohort A and B placebo groups were not fully comparable, which may have impacted the results of the cohort B primary analysis. To address this limitation, 